Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Citi puts Sage Group shares on 'positive catalyst watch' into FY results

(Sharecast News) - Sage Group rallied on Friday after Citi placed the shares on 'positive catalyst watch' into full-year results in November, saying it expects a "better-than-feared" update. Citi said Sage has been delivering rather resilient results in an uncertain backdrop, however, small moderation in growth and AI disruption related concerns have been stock overhangs.

The bank said it had revisited its positive investment thesis with a detailed look at the demand environment (SMEs) as well as bottom-up building blocks of Sage's growth.

"Our work supports confidence that Sage has right levers to sustain the growth, and potential to accelerate in a better macro set-up," it said. "AI would remain key topic of debate, at the same time Sage efforts on bringing and commercialising AI use cases should be more visible in FY26."

Citi noted that the shares have underperformed year to date and said it sees scope for consensus upgrades.

The bank is 7-10% ahead on FY26-27E earnings per share/free cash flow.

Citi maintained its 'buy' rating and 1,500p price target on the stock.

At 0910 BST, the shares were up 2.4% at 1,139p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.